Testosterone Enanthate 250mg/ml 10x1ml Ampullen by Aburaihan Iran

Usage

1. Review the compound's historical pharmaceutical documentation to confirm your dose is anchored in clinically studied ranges — typically 100–500mg per week for most male users.
2. Inspect the ampoule visually for particulate matter or discolouration; the solution should be clear to pale yellow — reject any ampoule with cloudiness or visible particles.
3. Score and snap the ampoule neck using the coloured break-ring or a sterile ampoule file, following the single-use design that Aburaihan built into the glass format.
4. Draw the full 1ml using an 18–21G drawing needle, then switch to a 23–25G, 1–1.5 inch injection needle to minimise tissue trauma at the injection site.
5. Administer via deep intramuscular injection into the gluteus medius, vastus lateralis, or deltoid — rotate sites each injection to reflect best practices developed over decades of clinical TRT delivery.
6. Record each injection date, ampoule batch number, and dose in a training log; this documentation habit mirrors pharmaceutical trial record-keeping and aids any monitoring blood work interpretation.

Warnings

Frequently asked questions

Where did Testosterone Enanthate originally come from and who first developed it?

Testosterone Enanthate was first synthesised and commercialised in the early 1950s by Squibb Pharmaceuticals in the United States under the brand name Delatestryl, approved in 1954. The enanthate ester was engineered to extend the half-life of testosterone by slowing ester hydrolysis at the injection depot, giving clinicians a practical once-weekly dosing tool for hypogonadism therapy — a pharmacological problem that shorter esters like propionate could not solve efficiently.

How has the clinical and performance use of Testosterone Enanthate evolved since the 1950s?

From its 1954 debut as a hypogonadism treatment, Testosterone Enanthate expanded into sport by the 1960s, was formally banned by the IOC in 1976, yet retained pharmaceutical-grade production throughout. Today it anchors both TRT protocols endorsed by endocrinology bodies such as the Endocrine Society and performance-enhancement regimens, making it one of the few compounds whose clinical legitimacy and off-label demand have coexisted for over seven decades.

Why did Aburaihan Iran become a significant producer of Testosterone Enanthate historically?

Aburaihan Pharmaceutical Company, founded and licensed in Iran, entered testosterone enanthate production as part of Iran's broader push toward domestic pharmaceutical self-sufficiency, particularly relevant following the Islamic Revolution and subsequent import restrictions. Their long production history — spanning from the 1970s onward — positioned them as a regionally dominant supplier whose output eventually reached international markets, building a reputation grounded in decades of consistent GMP-standard manufacturing rather than recent market entry.

What is the advantage of single-dose 1ml ampoules over multi-dose vials for Testosterone Enanthate storage?

Single-dose 1ml ampoules eliminate the microbiological contamination risk that accumulates in multi-dose vials each time a needle pierces the stopper. Once a glass ampoule is snapped open, the entire 250mg dose is drawn immediately with no residual product exposed to air or repeat puncture. For storage, sealed ampoules should be kept at 15–25 °C away from direct light; the sealed glass container maintains sterility and concentration integrity until the printed expiry date.

Is 250mg/ml a suitable concentration for someone beginning a Testosterone Enanthate protocol?

Yes — 250mg/ml is widely regarded as the most clinically practical concentration because a single 1ml ampoule delivers a complete standard dose without requiring fractional measurements that introduce dosing error. Beginner TRT protocols typically start at 100–150mg per week, meaning a single ampoule covers 1–2.5 weeks at those doses, making it straightforward to manage without dilution or overly small injection volumes that can cause injection-site irritation. (2) angle_used

Manufacturer

Aburaihan Pharmaceutical Company is an Iranian state-affiliated pharmaceutical manufacturer headquartered in Tehran, Iran, operating under licence from Iran's Food and Drug Administration (IFDA). The company's roots trace back to the 1970s, a period when Iran was investing heavily in domestic pharmaceutical infrastructure to reduce dependence on foreign drug imports — a strategic priority that intensified after 1979. Aburaihan built its reputation through consistent production of injectable hormonal preparations, with testosterone enanthate becoming one of its most internationally recognised products. The company's longevity in this category means its manufacturing team has accumulated institutional process knowledge across multiple regulatory eras, equipment generations, and pharmacopoeial standards — a depth of experience that shorter-lived producers cannot replicate. Its ampoules are recognisable worldwide among clinicians and informed end-users alike, a testament to sustained quality discipline rather than marketing.